Israel Englander Next Cure, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 72,119 shares of NXTC stock, worth $94,475. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,119

Previous 458,340 84.27%

Holding current value

$94,475

Previous $728,000 86.54%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.33 - $1.78 $513,673 - $687,473	-386,221 Reduced 84.27%	72,119 $98,000
Q2 2024 Aug 14, 2024	SELL	$1.17 - $2.49 $790,613 - $1.68 Million	-675,738 Reduced 59.58%	458,340 $728,000
Q1 2024 May 15, 2024	SELL	$1.13 - $2.23 $7,131 - $14,073	-6,311 Reduced 0.55%	1,134,078 $2.53 Million
Q4 2023 Feb 14, 2024	SELL	$1.03 - $1.45 $276,725 - $389,565	-268,666 Reduced 19.07%	1,140,389 $1.3 Million
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $66,098 - $83,634	-44,965 Reduced 3.09%	1,409,055 $2.54 Million
Q1 2023 May 15, 2023	BUY	$1.46 - $1.83 $170,855 - $214,153	117,024 Added 8.75%	1,454,020 $2.15 Million
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $145,791 - $372,983	121,493 Added 10.0%	1,336,996 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.19 $275,027 - $524,776	101,113 Added 9.07%	1,215,503 $3.34 Million
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.27 $341,667 - $532,717	101,085 Added 9.98%	1,114,390 $5.24 Million
Q1 2022 May 16, 2022	BUY	$4.76 - $6.24 $25,308 - $33,178	5,317 Added 0.53%	1,013,305 $4.93 Million
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $2.4 Million - $3.84 Million	421,860 Added 71.97%	1,007,988 $6.05 Million
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $1.23 Million - $1.47 Million	182,814 Added 45.33%	586,128 $3.95 Million
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $2.38 Million - $3.22 Million	313,220 Added 347.66%	403,314 $3.24 Million
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $23,063 - $32,631	2,351 Added 2.68%	90,094 $902,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $3.85 Million - $5.06 Million	-406,905 Reduced 82.26%	87,743 $956,000
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $2.93 Million - $7.62 Million	359,964 Added 267.27%	494,648 $4.35 Million
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $1.5 Million - $2.85 Million	70,967 Added 111.38%	134,684 $2.89 Million
Q1 2020 May 14, 2020	BUY	$32.32 - $58.37 $364,020 - $657,421	11,263 Added 21.47%	63,717 $2.36 Million
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $1.31 Million - $4.84 Million	52,454 New	52,454 $2.96 Million
Q3 2019 Nov 14, 2019	SELL	$15.73 - $41.6 $474,055 - $1.25 Million	-30,137 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.16 - $20.64 $426,739 - $622,027	30,137 New	30,137 $451,000

Others Institutions Holding NXTC

# of Institutions

Shares Held

15.9M

Call Options Held

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account